

Colon stenting as a bridge to surgery in obstructive colorectal cancer management

Dong Hyun Kim¹, Han Hee Lee²

¹Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju; ²Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Colonic stent placement is a commonly used bridging strategy for surgery in patients with obstructive colorectal cancer. The procedure involves the placement of a self-expandable metallic stent (SEMS) across the obstructive lesion to restore intestinal patency and alleviate the symptoms of obstruction. By allowing patients to receive surgery in a planned and staged manner with time for preoperative optimization and bowel preparation, stent placement may reduce the need for emergency surgery, which is associated with higher complication rates and poorer outcomes. This review focuses on the role of colon stenting as a bridge to surgery in the management of obstructive colorectal cancer. SEMS as a bridge to surgery for left-sided colon cancer has been demonstrated to be particularly useful; however, further research is needed for its application in cases of right-sided colon cancer. Colon stent placement also has limitations and potential complications including stent migration, re-obstruction, and perforation. However, the timing of curative surgery after SEMS placement remains inconclusive. Considering the literature to date, performing surgery at an interval of approximately 2 weeks is considered appropriate. Therefore, colonic stent placement may be an effective strategy as a bridge to surgery in patients with obstructive colorectal cancer.

Keywords: Colonic neoplasms; Colorectal surgery; Intestinal obstruction; Self-expandable metallic stents

INTRODUCTION

Colorectal cancer is one of the most common malignancies worldwide, and its prevalence is gradually increasing.^{1,2} Large bowel obstruction caused by colorectal cancer occurs in 7% to 29% of patients with this cancer.³⁻⁵ Conventionally, patients with obstructive colorectal cancer are treated with emergency surgery, which is associated with high morbidity and mortality

rates of 40% to 50% and 15% to 20%, respectively.⁶⁻⁸ Moreover, many patients who have undergone emergency surgery are left with a permanent colostomy,^{9,10} resulting in a markedly lower health-related quality of life than those without a colostomy.^{11,12} These patients experience worse outcomes because of higher morbidity and mortality rates than those who receive surgery electively.¹³⁻¹⁵

Colon stenting is a minimally invasive procedure that involves the insertion of a self-expandable metallic stent (SEMS) into the colon to relieve obstruction caused by a malignant tumor. Since the introduction of metallic stents in 1991 by Dohmoto,¹⁶ SEMSs have been widely applied as a palliative treatment for malignant colorectal obstruction in patients with incurable diseases.¹⁷ Colon stenting can be used as an alternative to emergency surgery in patients with colonic obstruction caused by malignant tumors. SEMS insertion relieves obstruction and allows the resumption of normal bowel function.

Received: May 23, 2023 **Revised:** July 23, 2023 **Accepted:** July 29, 2023

Correspondence: Han Hee Lee

Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea

E-mail: hanyee99@hanmail.net

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

During this time, the stent serves as a “bridge” to allow the patient to recover from the acute symptoms of the obstruction and prepare for elective surgery for curative intent. Tejero et al.¹⁸ first reported SEMS as a bridge to surgery (BTS) for malignant colorectal obstruction in 1994. Since then, several studies have demonstrated stent placement before elective surgery as a safe alternative to conventional emergent surgical management of malignant obstruction of the colon.^{10,19} Preoperative SEMS placement can prevent high-risk emergency surgery, increase primary anastomosis, and decrease stoma formation.²⁰ Additionally, SEMS use allows physicians to perform medical resuscitation, bowel preparation, optimization of comorbidities, and stage workup for colon cancer.^{19,21} This review describes the role of colon stenting as a BTS strategy in the management of obstructive colorectal cancer.

CURRENT MANAGEMENT OF MALIGNANT LEFT-SIDED COLONIC OBSTRUCTION

Clinical guidelines

Several clinical guidelines have addressed the issue of selecting between SEMS and emergency surgery in the management of left-sided malignant colonic obstruction.²²⁻²⁵ Recent guidelines have expanded the role of SEMS as a BTS in the curative treatment of left malignant colonic obstruction. In 2014, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines regarding SEMS placement for malignant obstructions did not recommend colonic SEMS placement as a bridge to elective surgery for the standard treatment of symptomatic left-sided malignant colonic obstruction.²⁶ This recommendation was strong and supported by high-quality evidence. SEMS use was only considered an alternative to emergency surgery in patients who were at high risk for postoperative morbidity and mortality. However, the ESGE guidelines from 2014 were updated in 2020.²² The new guidelines now support SEMS use as a valid alternative to emergency resection for managing symptomatic left-sided malignant colonic obstructions. The guidelines emphasize the importance of a shared decision-making process with patients, considering technical factors, as well as short- and long-term outcomes. Stenting is not recommended as a prophylactic procedure for an anticipated obstruction.

The guidelines of the American Society of Colon and Rectal Surgeons (ASCRS) for 2022 state that the choice between SEMS use and emergency resection should be individualized based on patient factors and the local expertise of the institution, thus

aligning with the ESGE 2020 guidelines.²³ The guidelines also recommend that a diverting colostomy may be an alternative to stenting. The European Society for Medical Oncology 2020 guidelines²⁴ state that colonic stenting can be used as a bridge to elective surgery, particularly in expert centers, for patients likely to have higher rates of postoperative complications after emergency surgery, such as those aged >70 years and/or those with an American Society of Anesthesiologists classification >II. According to the National Comprehensive Cancer Network 2021 guidelines,²⁵ one-stage colectomy with *en bloc* removal of the regional lymph nodes, resection with diversion, and diversion or stenting followed by colectomy are all possible options for managing resectable colon cancer with obstruction. Stents are generally considered in cases of distal cancer where a stent can facilitate decompression of the proximal colon, allowing for elective colectomy with a primary anastomosis at a later stage. Table 1 summarizes the guidelines for each type of colorectal stenting used as a BTS.

Comparison of outcomes between SEMS use vs. emergency surgery

In a recent meta-analysis that compared SEMS use and emergency surgery, 27 relevant studies with approximately 4,000 patients were included.²⁷ Only randomized controlled trials (RCTs) or high-quality non-randomized comparative studies were considered to ensure reliability and robustness. The meta-analysis indicated that SEMS use resulted in improved surgical and short-term survival outcomes compared with emergency surgery. These included a higher primary anastomosis rate, lower overall complication rate, increased lymph node harvest, shorter intensive care unit and hospital stays, and reduced 30-day mortality rates. However, the long-term oncological outcomes, presented as 3- and 5-year disease-free and overall survival rates afforded by SEMS use and emergency surgery, were similar.

In recent RCTs, the multicenter Enteral Stents for Colonic Obstruction (ESCO) trial conducted in Europe has demonstrated no statistically significant differences in overall survival, time to progression, and disease-free survival between stenting as a BTS and emergency surgery.²⁸ These findings were based on a median follow-up period of 37 months in the ESCO trial. An RCT conducted in the United Kingdom, the ColoRectal Endoscopic Stenting Trial, also demonstrated similar results between stenting and emergency surgery in terms of the 30-day postoperative mortality rate and duration of hospital stay. Furthermore, the stenting group in the RCT had significantly lower

Table 1. Summary of the latest guidelines for each situation in colorectal stenting as a BTS

Situation	Recommendations from various guidelines
Management of left-sided colonic obstruction	SEMS use as a valid alternative to emergency resection for managing symptomatic left-sided malignant colonic obstruction, emphasize the importance of a shared decision-making process with patients, considering technical factors as well as short- and long-term outcomes (ESGE 2020) Stenting is not recommended as a prophylactic procedure for anticipated obstructions (ESGE 2020) Choice between SEMS use and emergency resection should be individualized based on patient factors and the local expertise of the institution (ASCRS 2022) Colonic stenting can be used as a bridge to elective surgery, particularly in expert centers, for patients likely to have higher rates of postoperative complications after emergency surgery, such as those who aged >70 years and/or with an American Society of Anesthesiologists classification of >II (ESMO 2020) One-stage colectomy with <i>en bloc</i> removal of regional lymph nodes, resection with diversion, and diversion or stenting followed by colectomy are all possible options for the management of resectable colon cancer with obstruction (NCCN 2021)
Management of right-sided colonic obstruction	SEMS use can be considered a BTS even in the treatment of malignant right-sided colonic obstruction (ESGE 2020) Both the initial colectomy and initial endoscopic stent decompression with subsequent interval colectomy could be considered treatment options for patients with obstructing right or transverse colon cancer and curable disease (ASCRS 2022)
Perforation	Emergency resection should be considered in patients with stent-related perforation (ESGE 2020)
Migration	Even if migration occurs, early surgery should be performed without attempting stent re-insertion in the BTS group (ESGE 2020)
Stent re-obstruction	Early surgery rather than repeat colonic stenting when stent obstruction occurs in the BTS group (ESGE 2020)
Optimal timing of surgery after colon stenting	Performing elective surgery with a time interval of approximately 2 weeks after SEMS insertion (EGSE 2020)

BTS, bridge to surgery; SEMS, self-expandable metallic stent; ESGE, European Society of Gastrointestinal Endoscopy; ASCRS, American Society of Colon and Rectal Surgeons; ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network.

stoma formation rates than the emergency surgery group.²⁹

A major concern associated with SEMS use is the risk of perforation. Perforation can have a marked impact on the oncological outcomes of affected patients, leading to worse outcomes. In an RCT conducted by Sloothaak et al.,³⁰ SEMS use was associated with a higher 5-year overall recurrence rate than emergency surgery. This finding was attributed to patients with stent perforation who had significantly higher overall recurrence rates than those without stent perforation (83% vs. 34%, $p < 0.01$) as well as a higher 5-year cumulative incidence of locoregional recurrence (50% vs. 10%, $p = 0.053$). Two RCTs conducted in the Netherlands that compared SEMS use and emergency surgery were stopped prematurely because of the unexpectedly high perforation rate.^{31,32}

CURRENT MANAGEMENT OF MALIGNANT RIGHT-SIDED COLONIC OBSTRUCTION

Clinical guidelines

Decompression procedures for proximal colonic obstruction are less common than those for distal obstruction. This can be

attributed to several factors. First, the technical success rate for right-sided obstruction has been reported to be slightly lower than that for left-sided obstruction.^{33,34} Second, the long distance from the anus and the tortuosity of the bowel make proximal colonic stenting considerably more challenging than distal colonic stenting. Furthermore, more time and experience are required to achieve successful outcomes.³⁵

Segmental resection with ileocolic anastomosis is considered a safe surgical approach for managing malignant right-sided colonic obstruction and has been performed in most cases.³⁶ Hence, most studies evaluating stenting as a BTS have primarily focused on left-sided obstructions. However, a previous population-based study has reported that a bridging strategy involving SEMS use or diverting loop ileostomy was associated with lower mortality rates than primary resection in cases of malignant right-sided colonic obstruction.³⁷ Subsequently, SEMS use has been increasingly implemented in the management of malignant right-sided colonic obstruction. Recently, guidelines have been established for SEMS use in this context.

The ESGE 2014 guidelines recommend surgical resection as the preferred treatment option for malignant obstruction of the

proximal colon, and stenting is not widely recommended for right-sided obstruction owing to limited evidence.²⁶ However, in the ESGE 2020 guidelines, the status of SEMS use has been upgraded, and it is specified that SEMS use can be considered a BTS strategy even in the treatment of malignant right-sided colonic obstruction.²² This indicates that the evidence and recommendations for SEMS use in cases of right-sided obstruction have evolved, and SEMS use is now recognized as a potential treatment option in this context.

The most recent ASCRS 2022 guidelines for the management of colon cancer acknowledge that both initial colectomy and initial endoscopic stent decompression with subsequent interval colectomy could be considered treatment options for patients with obstructing right or transverse colon cancer and curable disease.²³ Evolving guidelines, such as the ESGE 2020 and ASCRS 2022 guidelines, reflect the increasing acceptance and recognition of SEMS use as a BTS in cases of malignant right-sided colon obstruction. These changes are based on accumulating evidence from studies and clinical experience, suggesting that SEMS placement can be a safe and effective approach for managing malignant right-sided colonic obstruction in selected patients. Clinicians need to stay updated on the latest guidelines to inform their clinical decision-making and provide optimal care to patients with this condition.

Comparison of outcomes between SEMS use and emergency surgery

Several retrospective studies have compared SEMS placement with emergency surgery in terms of short-term treatment outcomes and long-term oncological and survival outcomes. A nationwide database study conducted in Japan investigated perioperative outcomes in 1,500 matched patients who underwent emergency right colectomy or SEMS use.³⁸ The study has reported that SEMS use afforded more favorable perioperative outcomes, including a higher rate of laparoscopic utilization, fewer stomas, and shorter length of hospital stay. A previous systematic review of procedure-related morbidity and mortality has demonstrated that stent placement and elective resection were associated with lower major morbidity and mortality rates as well as fewer anastomotic leakages and permanent ileostomies.³⁹ Another recent systematic review has also demonstrated that staged treatment by decompression or stenting was associated with lower mortality rates, fewer complications, and fewer anastomotic leaks and stoma creations than emergency resection.⁴⁰

CLINICAL OUTCOMES OF SEMS USE

Technical and clinical success

Technical success was defined as successful stent placement across an obstructed colonic segment. Clinical success refers to the effectiveness of the stent in relieving the symptoms of colonic obstruction and improving bowel function.⁴¹ Technical success rates of 81% to 100% have been reported in observational studies. The clinical success rate for colon stenting has been reported to be 65% to 100%.⁴¹⁻⁴⁹ This indicates that in the vast majority of cases, colorectal stents could be placed in the correct position and fully expanded to relieve obstruction. Most patients experience symptom improvement after stent placement, such as relief from abdominal pain and resumption of normal bowel movements. Some studies have reported higher technical and clinical success rates when a stent is inserted by an operator with experience in performing at least 10 colon stent procedures.⁵⁰ Meanwhile, a lesion length of >5 cm and the presence of curved lesions are associated with a low clinical success rate.⁴⁹

Complications

The major complications associated with colon stenting include perforation, migration, and re-obstruction. In addition, complications, such as ulceration, hematochezia, infection/fever, and tenesmus, can occur. The overall complication rate associated with SEMS use as a BTS has been reported to be 7% to 23%.^{51,52} Complete obstruction, a stent diameter of ≤ 22 mm, and operator experience are significant factors affecting the complication risk associated with SEMS use as a BTS.⁵¹

Perforations may also occur during stent insertion or expansion. Stent migration may lead to obstruction or perforation if the stent moves or is dislodged after placement. Bowel re-obstruction may occur due to ingrowth or overgrowth of the tumor into the stent lumen or stool impaction within the stent lumen. The risk of infection, especially bacteremia, may increase with stent insertion, particularly in cases of complete obstruction.⁵¹ However, in one RCT, the use of prophylactic antibiotics was not effective in preventing infections associated with SEMS use.⁵³

1) Perforation

Perforation is a potential complication of colonic stent insertion. It occurs when the stent causes a tear or hole in the colonic wall. Perforation can be a serious complication when it results in the

development of peritonitis or sepsis.⁵² Stent-related perforation may result from guidewire or catheter malpositioning, stricture dilation, and proximal colonic distension because of inadequate colonic decompression or excessive air insufflation.^{52,54,55} Old age, long segment involvement, and angulated strictures have been identified as risk factors for perforation.^{49,56,57} A previous prospective study and systematic review have reported perforation rates of 3% to 5%.^{19,48,52,58-60} Meanwhile, some studies have reported high perforation rates of 10% to 13%.^{31,61} In a meta-analysis of 4,086 patients, an overall perforation rate of 7.4% was reported.⁶² “Silent” microperforations, which are perforations that can be detected only by a pathologic examination, were also identified in 1% to 20% of cases.^{31,52,61,63} The rates may vary depending on whether the pathologist actively searches for microperforations.^{52,64}

Stent-related perforation can lead to poor oncological outcomes. According to a recent meta-analysis on stenting as a BTS,⁶⁵ the occurrence of stent-related perforation was associated with an increased risk of local tumor recurrence, whereas no significant difference was observed in terms of systemic recurrence. In terms of survival, several reports have indicated that stent-related perforation is associated with high mortality rates.^{48,66,67} However, when considering only the BTS setting, even if perforation occurred, no significant differences were observed in 3- and 5-year overall survival rates between the groups with and without stent-related perforations.⁶⁵ The ESGE guidelines recommend considering emergency resection in patients with stent-related perforation.²²

2) Migration

Several studies have reported an SEMS migration rate of 1% to 20%.^{19,44,47,48,63,64,68-72} Migration is another potential complication of colon stent insertion and occurs when the SEMS moves out of its intended position in the colon. In two meta-analyses, the risk of SEMS migration was lower in the uncovered stent group than in the covered stent group.^{73,74} The use of stents of inappropriate sizes (e.g., an SEMS that is too small) or incorrect stent placement, such as SEMS placement in a tortuous portion of the colon, are factors that could result in more frequent SEMS migration.^{44,64,75} According to the ESGE guidelines, even if stent migration occurs, early surgery without attempting stent re-insertion is recommended in the BTS group.²² However, no well-designed comparative studies on early surgery and stent re-insertion have been conducted.

3) Stent re-obstruction

Stent re-obstruction is a potential complication of colonic stent insertion and occurs when the stent is blocked or occluded again after successful initial placement. Several studies have reported rates of SEMS re-obstruction of 3% to 18%.^{47,76,77} Stent occlusion occurs because of the overgrowth of malignant tissue, fecal impaction, or tumor ingrowth.^{47,78} Longer follow-up duration is a risk factor for stent re-obstruction.^{47,76,79,80} In cases in which stenting is a BTS, stent re-obstruction is less frequent than that in cases of palliative stenting because the period of stent maintenance is relatively short.⁵¹ Uncovered stents have been reported to be more prone to tumor ingrowth, whereas covered stents were associated with higher risks of stent migration and tumor overgrowth.⁸¹

Re-obstruction can be managed using stent replacement or stent-in-stent techniques in instances of palliative stenting.^{82,83} However, in the BTS group, the surgery was typically performed before the occurrence of re-obstruction due to tumor ingrowth. Therefore, in the context of stenting as a BTS, ensuring proper stent expansion during insertion and preventing migration would be better than being concerned regarding stent ingrowth. The ESGE guidelines recommend early surgery rather than repeat colonic stenting when stent obstruction occurs in the BTS group.²²

OPTIMAL TIMING OF SURGERY AFTER COLON STENTING

Current guidelines

The optimal timing of surgery after colonic stent insertion remains debatable, and no clear consensus on the ideal interval between stent placement and surgical intervention has been established. Changes were made to the ESGE guidelines. The 2014 ESGE guidelines recommend elective surgery within 5 to 10 days after SEMS insertion.²⁶ However, the 2020 ESGE guidelines recommend performing elective surgery within a time interval of approximately 2 weeks after SEMS insertion.²² The time interval for surgery after colonic stenting has been discussed and analyzed depending on the balance between surgery-related adverse events and tumoral systemic and local recurrences owing to delays.

Recent study results

Many studies have been conducted to determine the appropriate timing for surgery after SEMS use. Broholm et al.⁸⁴ have

reported that delayed elective surgery (≥ 18 days) after SEMS insertion could increase the risk of metastasis. Abdussamet Bozkurt et al.⁸⁵ suggested that an interval of 7 to 9 days after SEMS insertion is sufficient, because extending this duration could increase the risk of re-obstruction and emergency surgery. Kye et al.⁸⁶ conducted a study by dividing the interval between stenting and surgery into three groups: within 7 days, 8 to 14 days, and 15 days later. In this study, disease-free and overall survival was superior in the within 7 days group, whereas the rates of short-term postoperative complications were similar among the three groups.

However, some studies have suggested that slightly delaying the surgery is better. Matsuda et al.⁸⁷ have reported that an operation interval of >15 days reduced operation-related complications such as anastomosis site leakage and *Clostridioides difficile*-associated colitis. Another report has stated that the risk of anastomotic leakage significantly reduced when surgery was delayed for ≥ 10 days.⁸⁸ de Roos et al.⁸⁹ divided two groups by the interval between SEMS use and surgery: <4 weeks and ≥ 4 weeks. The later operation group demonstrated better 5-year recurrence-free survival (82.1% vs. 63.2%) and 5-year overall survival (75% vs. 51.4%). Recently, Oh et al.⁹⁰ formed three groups based on the interval between SEMS use and operation (group 1 [≤ 2 weeks], group 2 [2–3 weeks], and group 3 [>3 weeks]). In this study, the bridging interval did not affect SEMS-related complications, resection-related complications, 90-day mortality, permanent stoma formation, 3-year disease-free survival, or 3-year overall survival. Laparoscopic surgery rates were significantly higher in groups 2 and 3 than in group 1 (83.7% and 81.0%, respectively, vs. 53.2%). Furthermore, the rate of stoma formation directly after resection was significantly higher in group 1 than in groups 2 and 3 (21.3% vs. 2.3% and 6.9%, respectively). Because these studies demonstrated conflicting results, further studies are needed to confirm these findings and establish clear guidelines for the optimal timing of surgery after colon stent insertion.

CONCLUSIONS

As a treatment for intestinal obstruction caused by a malignant tumor, colonic stent insertion can be an effective strategy as a BTS in patients with obstructive colorectal cancer. Recently, various studies have reported that preoperative SEMS insertion affords superior treatment results compared to emergency surgery, and its indications are gradually expanding. Therefore,

clearly understanding the indications and methods of stent implantation before surgery is necessary to improve patient prognosis and reduce complications.

Conflicts of Interest

The authors have no potential conflicts of interest.

Funding

None.

Author Contributions

Conceptualization: all authors; Data curation: DHK; Formal analysis: HHL; Writing—original draft: all authors; Writing—review & editing: all authors.

ORCID

Dong Hyun Kim

<https://orcid.org/0000-0001-5778-1264>

Han Hee Lee

<https://orcid.org/0000-0002-8244-374X>

REFERENCES

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
2. Jullumstrø E, Wibe A, Lydersen S, et al. Colon cancer incidence, presentation, treatment and outcomes over 25 years. *Colorectal Dis* 2011;13:512–518.
3. Cheynel N, Cortet M, Lepage C, et al. Trends in frequency and management of obstructing colorectal cancers in a well-defined population. *Dis Colon Rectum* 2007;50:1568–1575.
4. Frago R, Ramirez E, Millan M, et al. Current management of acute malignant large bowel obstruction: a systematic review. *Am J Surg* 2014;207:127–138.
5. Kim JS, Hur H, Min BS, et al. Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery. *World J Surg* 2009;33:1281–1286.
6. Zhang Y, Shi J, Shi B, et al. Self-expanding metallic stent as a bridge to surgery versus emergency surgery for obstructive colorectal cancer: a meta-analysis. *Surg Endosc* 2012;26:110–119.
7. Tekkis PP, Kinsman R, Thompson MR, et al. The Association of Coloproctology of Great Britain and Ireland study of large bowel obstruction caused by colorectal cancer. *Ann Surg* 2004;240:76–81.
8. Leitman IM, Sullivan JD, Brams D, et al. Multivariate analysis of

- morbidity and mortality from the initial surgical management of obstructing carcinoma of the colon. *Surg Gynecol Obstet* 1992;174:513–518.
9. Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. *Br J Surg* 1994;81:1270–1276.
 10. Martinez-Santos C, Lobato RF, Fradejas JM, et al. Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates. *Dis Colon Rectum* 2002;45:401–406.
 11. Negent KP, Daniels P, Steward B, et al. Quality of life in stoma patients. *Dis Colon Rectum* 1999;42:1569–1574.
 12. Park JJ, Del Pino A, Orsay CP, et al. Stoma complications: the Cook County Hospital experience. *Dis Colon Rectum* 1999;42:1575–1580.
 13. Iversen LH, Bülow S, Christensen IJ, et al. Postoperative medical complications are the main cause of early death after emergency surgery for colonic cancer. *Br J Surg* 2008;95:1012–1019.
 14. Cuffy M, Abir F, Audisio RA, et al. Colorectal cancer presenting as surgical emergencies. *Surg Oncol* 2004;13:149–157.
 15. McArdle CS, Hole DJ. Emergency presentation of colorectal cancer is associated with poor 5-year survival. *Br J Surg* 2004;91:605–609.
 16. Dohmoto M. New method-endoscopic implantation of rectal stent in palliative treatment of malignant stenosis. *Endoscopia Digestiva* 1991;3:1507–1512.
 17. Tilney HS, Lovegrove RE, Purkayastha S, et al. Comparison of colonic stenting and open surgery for malignant large bowel obstruction. *Surg Endosc* 2007;21:225–233.
 18. Tejero E, Mainar A, Fernández L, et al. New procedure for the treatment of colorectal neoplastic obstructions. *Dis Colon Rectum* 1994;37:1158–1159.
 19. Khot UP, Lang AW, Murali K, et al. Systematic review of the efficacy and safety of colorectal stents. *Br J Surg* 2002;89:1096–1102.
 20. Cennamo V, Luigiano C, Coccolini F, et al. Meta-analysis of randomized trials comparing endoscopic stenting and surgical decompression for colorectal cancer obstruction. *Int J Colorectal Dis* 2013;28:855–863.
 21. Cirocchi R, Farinella E, Trastulli S, et al. Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and meta-analysis. *Surg Oncol* 2013;22:14–21.
 22. van Hooft JE, Veld JV, Arnold D, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline: update 2020. *Endoscopy* 2020;52:389–407.
 23. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the management of colon cancer. *Dis Colon Rectum* 2022;65:148–177.
 24. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2020;31:1291–1305.
 25. Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021;19:329–359.
 26. van Hooft JE, van Halsema EE, Vanbiervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Gastrointest Endosc* 2014;80:747–761.
 27. Spannenburg L, Sanchez Gonzalez M, Brooks A, et al. Surgical outcomes of colonic stents as a bridge to surgery versus emergency surgery for malignant colorectal obstruction: a systematic review and meta-analysis of high quality prospective and randomised controlled trials. *Eur J Surg Oncol* 2020;46:1404–1414.
 28. Arezzo A, Forcignanò E, Bonino MA, et al. Long-term oncologic results after stenting as a bridge to surgery versus emergency surgery for malignant left-sided colonic obstruction: a multicenter randomized controlled trial (ESCO Trial). *Ann Surg* 2020;272:703–708.
 29. CReST Collaborative Group. Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial. *Br J Surg* 2022;109:1073–1080.
 30. Sloothaak DA, van den Berg MW, Dijkgraaf MG, et al. Oncological outcome of malignant colonic obstruction in the Dutch Stent-In 2 trial. *Br J Surg* 2014;101:1751–1757.
 31. van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. *Lancet Oncol* 2011;12:344–352.
 32. van Hooft JE, Fockens P, Marinelli AW, et al. Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. *Endoscopy* 2008;40:184–191.
 33. Yoon JY, Jung YS, Hong SP, et al. Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc* 2011;74:858–868.
 34. Cho YK, Kim SW, Lee BI, et al. Clinical outcome of self-expandable metal stent placement in the management of malignant proximal colon obstruction. *Gut Liver* 2011;5:165–170.
 35. Kuwai T, Yamaguchi T, Imagawa H, et al. Factors related to difficult self-expandable metallic stent placement for malignant colonic obstruction: a post-hoc analysis of a multicenter study across Japan. *Dig Endosc* 2019;31:51–58.

36. Morita S, Ikeda K, Komori T, et al. Outcomes in colorectal surgeon-driven management of obstructing colorectal cancers. *Dis Colon Rectum* 2016;59:1028–1033.
37. Amelung FJ, Consten ECJ, Siersema PD, et al. A population-based analysis of three treatment modalities for malignant obstruction of the proximal colon: acute resection versus stent or stoma as a bridge to surgery. *Ann Surg Oncol* 2016;23:3660–3668.
38. Sakamoto T, Fujiogi M, Lefor AK, et al. Stent as a bridge to surgery or immediate colectomy for malignant right colonic obstruction: propensity-scored, national database study. *Br J Surg* 2020;107:1354–1362.
39. Amelung FJ, de Beaufort HW, Siersema PD, et al. Emergency resection versus bridge to surgery with stenting in patients with acute right-sided colonic obstruction: a systematic review focusing on mortality and morbidity rates. *Int J Colorectal Dis* 2015;30:1147–1155.
40. Boeding JRE, Ramphal W, Rijken AM, et al. A systematic review comparing emergency resection and staged treatment for curable obstructing right-sided colon cancer. *Ann Surg Oncol* 2021;28:3545–3555.
41. Kim SY, Kwon SH, Oh JH. Radiologic placement of uncovered stents for the treatment of malignant colorectal obstruction. *J Vasc Interv Radiol* 2010;21:1244–1249.
42. Kim H, Kim SH, Choi SY, et al. Fluoroscopically guided placement of self-expandable metallic stents and stent-grafts in the treatment of acute malignant colorectal obstruction. *J Vasc Interv Radiol* 2008;19:1709–1716.
43. Shrivastava V, Tariq O, Tiam R, et al. Palliation of obstructing malignant colonic lesions using self-expanding metal stents: a single-center experience. *Cardiovasc Intervent Radiol* 2008;31:931–936.
44. Kim JH, Song HY, Li YD, et al. Dual-design expandable colorectal stent for malignant colorectal obstruction: comparison of flared ends and bent ends. *AJR Am J Roentgenol* 2009;193:248–254.
45. Alcantara M, Serra X, Bombardó J, et al. Colorectal stenting as an effective therapy for preoperative and palliative treatment of large bowel obstruction: 9 years' experience. *Tech Coloproctol* 2007;11:316–322.
46. Selinger CP, Ramesh J, Martin DF. Long-term success of colonic stent insertion is influenced by indication but not by length of stent or site of obstruction. *Int J Colorectal Dis* 2011;26:215–218.
47. Yoon J, Kwon SH, Lee CK, et al. Radiologic placement of uncovered stents for the treatment of malignant colonic obstruction proximal to the descending colon. *Cardiovasc Intervent Radiol* 2017;40:99–105.
48. Sebastian S, Johnston S, Geoghegan T, et al. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. *Am J Gastroenterol* 2004;99:2051–2057.
49. Little MW, Oakley T, Briggs JH, et al. Technical and clinical outcomes following colonic stenting: a seven-year analysis of 268 procedures. *Cardiovasc Intervent Radiol* 2016;39:1471–1478.
50. Geraghty J, Sarkar S, Cox T, et al. Management of large bowel obstruction with self-expanding metal stents: a multicentre retrospective study of factors determining outcome. *Colorectal Dis* 2014;16:476–483.
51. Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors. *Gastrointest Endosc* 2010;71:560–572.
52. Saito S, Yoshida S, Isayama H, et al. A prospective multicenter study on self-expandable metallic stents as a bridge to surgery for malignant colorectal obstruction in Japan: efficacy and safety in 312 patients. *Surg Endosc* 2016;30:3976–3986.
53. Kim JS, Lee WS, Chung CY, et al. Clinical impact of prophylactic antibiotic treatment for self-expandable metallic stent insertion in patients with malignant colorectal obstruction. *Gastroenterol Res Pract* 2015;2015:416142.
54. Baron TH, Song LM, Repici A. Role of self-expandable stents for patients with colon cancer (with videos). *Gastrointest Endosc* 2012;75:653–662.
55. Han SH, Lee JH. Colonic stent-related complications and their management. *Clin Endosc* 2014;47:415–419.
56. Lee YJ, Yoon JY, Park JJ, et al. Clinical outcomes and factors related to colonic perforations in patients receiving self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc* 2018;87:1548–1557.
57. Boyle DJ, Thorn C, Saini A, et al. Predictive factors for successful colonic stenting in acute large-bowel obstruction: a 15-year cohort analysis. *Dis Colon Rectum* 2015;58:358–362.
58. Jiménez-Pérez J, Casellas J, García-Cano J, et al. Colonic stenting as a bridge to surgery in malignant large-bowel obstruction: a report from two large multinational registries. *Am J Gastroenterol* 2011;106:2174–2180.
59. Meisner S, González-Huix F, Vandervoort JG, et al. Self-expandable metal stents for relieving malignant colorectal obstruction: short-term safety and efficacy within 30 days of stent procedure in 447 patients. *Gastrointest Endosc* 2011;74:876–884.
60. Watt AM, Faragher IG, Griffin TT, et al. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. *Ann Surg* 2007;246:24–30.
61. Pirlet IA, Slim K, Kwiatkowski F, et al. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic ob-

- struction: a multicenter randomized controlled trial. *Surg Endosc* 2011;25:1814–1821.
62. van Halsema EE, van Hoof JE, Small AJ, et al. Perforation in colorectal stenting: a meta-analysis and a search for risk factors. *Gastrointest Endosc* 2014;79:970–982.
 63. Tomita M, Saito S, Makimoto S, et al. Self-expandable metallic stenting as a bridge to surgery for malignant colorectal obstruction: pooled analysis of 426 patients from two prospective multicenter series. *Surg Endosc* 2019;33:499–509.
 64. Verstockt B, Van Driessche A, De Man M, et al. Ten-year survival after endoscopic stent placement as a bridge to surgery in obstructing colon cancer. *Gastrointest Endosc* 2018;87:705–713.
 65. Balciscueta I, Balciscueta Z, Uribe N, et al. Long-term outcomes of stent-related perforation in malignant colon obstruction: a systematic review and meta-analysis. *Int J Colorectal Dis* 2020;35:1439–1451.
 66. Manes G, de Bellis M, Fuccio L, et al. Endoscopic palliation in patients with incurable malignant colorectal obstruction by means of self-expanding metal stent: analysis of results and predictors of outcomes in a large multicenter series. *Arch Surg* 2011;146:1157–1162.
 67. Park YE, Park Y, Park SJ, et al. Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration. *Surg Endosc* 2019;33:1225–1234.
 68. Athreya S, Moss J, Urquhart G, et al. Colorectal stenting for colonic obstruction: the indications, complications, effectiveness and outcome: 5 year review. *Eur J Radiol* 2006;60:91–94.
 69. Clark JS, Buchanan GN, Khawaja AR, et al. Use of the Bard Memotherm self-expanding metal stent in the palliation of colonic obstruction. *Abdom Imaging* 2003;28:518–524.
 70. Currie A, Christmas C, Aldean H, et al. Systematic review of self-expanding stents in the management of benign colorectal obstruction. *Colorectal Dis* 2014;16:239–245.
 71. Di Mitri R, Mocciaro F, Traina M, et al. Self-expandable metal stents for malignant colonic obstruction: data from a retrospective regional SIED-AIGO study. *Dig Liver Dis* 2014;46:279–282.
 72. Rodrigues-Pinto E, Morais R, Coelho C, et al. Bridge-to-surgery versus emergency surgery in the management of left-sided acute malignant colorectal obstruction: efficacy, safety and long-term outcomes. *Dig Liver Dis* 2019;51:364–372.
 73. Mashar M, Mashar R, Hajibandeh S. Uncovered versus covered stent in management of large bowel obstruction due to colorectal malignancy: a systematic review and meta-analysis. *Int J Colorectal Dis* 2019;34:773–785.
 74. Zhang Y, Shi J, Shi B, et al. Comparison of efficacy between uncovered and covered self-expanding metallic stents in malignant large bowel obstruction: a systematic review and meta-analysis. *Colorectal Dis* 2012;14:e367–e374.
 75. Rayhanabad J, Abbas MA. Long-term outcome of endoscopic colorectal stenting for malignant and benign disease. *Am Surg* 2009;75:897–900.
 76. Lee HJ, Hong SP, Cheon JH, et al. Clinical outcomes of self-expandable metal stents for malignant rectal obstruction. *Dis Colon Rectum* 2018;61:43–50.
 77. Park SJ, Lee KY, Kwon SH, et al. Stenting as a bridge to surgery for obstructive colon cancer: does it have surgical merit or oncologic demerit? *Ann Surg Oncol* 2016;23:842–848.
 78. Fiori E, Lamazza A, Sterpetti AV, et al. Endoscopic stenting for colorectal cancer: lessons learned from a 15-year experience. *J Clin Gastroenterol* 2018;52:418–422.
 79. Imai M, Kamimura K, Takahashi Y, et al. The factors influencing long-term outcomes of stenting for malignant colorectal obstruction in elderly group in community medicine. *Int J Colorectal Dis* 2018;33:189–197.
 80. Sousa M, Pinho R, Proença L, et al. Predictors of complications and mortality in patients with self-expanding metallic stents for the palliation of malignant colonic obstruction. *GE Port J Gastroenterol* 2017;24:122–128.
 81. Yang Z, Wu Q, Wang F, et al. A systematic review and meta-analysis of randomized trials and prospective studies comparing covered and bare self-expandable metal stents for the treatment of malignant obstruction in the digestive tract. *Int J Med Sci* 2013;10:825–835.
 82. Yoon JY, Park SJ, Hong SP, et al. Outcomes of secondary self-expandable metal stents versus surgery after delayed initial palliative stent failure in malignant colorectal obstruction. *Digestion* 2013;88:46–55.
 83. Yoon JY, Jung YS, Hong SP, et al. Outcomes of secondary stent-in-stent self-expandable metal stent insertion for malignant colorectal obstruction. *Gastrointest Endosc* 2011;74:625–633.
 84. Broholm M, Kobborg M, Frostberg E, et al. Delay of surgery after stent placement for resectable malignant colorectal obstruction is associated with higher risk of recurrence. *Int J Colorectal Dis* 2017;32:513–516.
 85. Abdussamet Bozkurt M, Gonenc M, Kapan S, et al. Colonic stent as bridge to surgery in patients with obstructive left-sided colon cancer. *JLS* 2014;18:e2014.00161.
 86. Kye BH, Kim JH, Kim HJ, et al. The optimal time interval between the placement of self-expandable metallic stent and elective surgery in patients with obstructive colon cancer. *Sci Rep* 2020;10:9502.
 87. Matsuda A, Miyashita M, Matsumoto S, et al. Optimal interval from placement of a self-expandable metallic stent to surgery in patients with malignant large bowel obstruction: a preliminary study. *Surg Laparosc Endosc Percutan Tech* 2018;28:239–244.

88. Lee GJ, Kim HJ, Baek JH, et al. Comparison of short-term outcomes after elective surgery following endoscopic stent insertion and emergency surgery for obstructive colorectal cancer. *Int J Surg* 2013;11:442–446.
89. de Roos MA, Hugen N, Hazebroek EJ, et al. Delayed surgical resection of primary left-sided obstructing colon cancer is associated with improved short- and long-term outcomes. *J Surg Oncol* 2021; 124:1146–1153.
90. Oh HH, Hong JY, Kim DH, et al. Differences in clinical outcomes according to the time interval between the bridge to surgery stenting and surgery for left-sided malignant colorectal obstruction. *World J Surg Oncol* 2022;20:178.